Protalix BioTherapeutics Inc. (PLX) and Its Peers Financial Results Comparison

Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) is a company in the Biotechnology industry and that’s how we contrast it to its rivals. The comparing will be based on the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Institutional & Insider Ownership

Protalix BioTherapeutics Inc. has 9.82% of its shares owned by institutional investors and an average of 50.88% institutional ownership for its rivals. 6.23% of Protalix BioTherapeutics Inc. shares are owned by company insiders. Comparatively, 8.18% of all Biotechnology companies shares are owned by company insiders.


On first table we have Protalix BioTherapeutics Inc. and its rivals’ net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics Inc. -530.24% 0.00% 0.00%
Industry Average 1,464.25% 88.44% 21.62%

Earnings & Valuation

The following data compares Protalix BioTherapeutics Inc. and its rivals’ valuation, top-line revenue and net income.

Net Income Gross Revenue Price/Earnings Ratio
Protalix BioTherapeutics Inc. 51.38M 9.69M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Ratings

Table 3 provides summary of current ratings for Protalix BioTherapeutics Inc. and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Protalix BioTherapeutics Inc. 0 0 0 0.00
Industry Average 1.17 1.78 2.01 2.68

The rivals have a potential upside of 173.20%.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Protalix BioTherapeutics Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Protalix BioTherapeutics Inc. -3.09% -9.42% -14.23% -9.66% -35.18% -36.46%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Protalix BioTherapeutics Inc. had bearish trend while Protalix BioTherapeutics Inc.’s rivals had bullish trend.


Protalix BioTherapeutics Inc. does not pay a dividend.


Protalix BioTherapeutics Inc.’s competitors show that they’re better in 4 of the 4 factors compared to the company itself.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.